A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

  1. Lookup NU author(s)
  2. Dr Britta Vormoor
  3. Dr Gareth Veal
  4. Melanie Griffin
  5. Professor Julie Irving
  6. Lynne Minto
  7. Marian Case
  8. Claire Schwab
  9. Professor Christine Harrison
  10. Professor Josef Vormoor
Author(s)Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J
Publication type Article
JournalPediatric Blood & Cancer
Year2017
Volume64
Issue6
Pagese26351 1-4
ISSN (print)1545-5009
ISSN (electronic)1545-5017
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
PublisherJohn Wiley & Sons, Inc.
URLhttps://doi.org/10.1002/pbc.26351
DOI10.1002/pbc.26351
Actions    Link to this publication

Altmetrics provided by Altmetric

Share